I
n response to rising drug costs, advocacy groups in the U.K. are pushing the government to make medicines that are developed with taxpayer funds more accessible. And in a new report, they suggest the U.K. government take steps that activists in the U.S. have also begun to demand.
Specifically, the U.K. groups argue the government ought to require drug makers to disclose R&D costs and licensing terms for medicines that are discovered with taxpayer money. Licenses should include provisions that somehow guarantee patient access. And prices should not automatically be linked to R&D costs incurred by companies.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Nothing wrong with this initiative!
If failing memory serves, when ABT – now AbbVee – acquired the company that had the ‘rights’ to Humira, Miles White had to cough up $6+ Billion [2001] USD to purchase said entity. Mayhaps the claw back should be from them?